MedPath

HOKKAIDO GASTROINTESTINAL CANCER STUDY GROUP

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer

Phase 3
Suspended
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: L-Plat
Drug: Campto, Topotesin
First Posted Date
2006-04-21
Last Posted Date
2007-11-01
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
200
Registration Number
NCT00316745
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan

Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: Campto, Topotesin
First Posted Date
2005-09-21
Last Posted Date
2007-11-01
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
40
Registration Number
NCT00209651
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 2
Suspended
Conditions
Gastric Cancer
First Posted Date
2005-09-21
Last Posted Date
2006-02-02
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
40
Registration Number
NCT00209664
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.

Phase 1
Suspended
Conditions
Gastric Cancer
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
50
Registration Number
NCT00209729
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.

Phase 1
Completed
Conditions
Esophageal Cancer
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
30
Registration Number
NCT00209716
Locations
🇯🇵

・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

Phase 3
Conditions
Colorectal Cancer
Interventions
Drug: USEL/Leucovorin
Drug: Krestin
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
340
Registration Number
NCT00209742
Locations
🇯🇵

・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan

Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.

Phase 1
Completed
Conditions
Esophageal Cancer
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-05-26
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
30
Registration Number
NCT00209690
Locations
🇯🇵

・ Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine), Sapporo, Hokkaido, Japan

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1
Suspended
Conditions
Pancreatic Cancer
First Posted Date
2005-09-21
Last Posted Date
2007-11-01
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
40
Registration Number
NCT00209677
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer

Phase 2
Terminated
Conditions
Colorectal Cancer
First Posted Date
2005-09-21
Last Posted Date
2006-04-21
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
30
Registration Number
NCT00209703
Locations
🇯🇵

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine), Sapporo, Hokkaido, Japan

Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Phase 1
Completed
Conditions
Gastric Cancer
First Posted Date
2005-09-21
Last Posted Date
2006-04-21
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Target Recruit Count
24
Registration Number
NCT00209638
© Copyright 2025. All Rights Reserved by MedPath